These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 22460117)
21. Accelerating access to treatments for rare diseases. Dunoyer M Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499 [TBL] [Abstract][Full Text] [Related]
22. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future? Oo C; Rusch LM J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513 [No Abstract] [Full Text] [Related]
23. Orphan drug development: an economically viable strategy for biopharma R&D. Meekings KN; Williams CS; Arrowsmith JE Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309 [TBL] [Abstract][Full Text] [Related]
24. Post-authorisation assessment of orphan drugs. Hollak CEM; Biegstraaten M; Levi M; Hagendijk R Lancet; 2015 Nov; 386(10007):1940-1941. PubMed ID: 26841744 [No Abstract] [Full Text] [Related]
25. Regulators adopt more orphan drugs. Reardon S Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293 [No Abstract] [Full Text] [Related]
26. The routes to orphan drug designation--our recent experience at the FDA. Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120 [No Abstract] [Full Text] [Related]
27. Protein replacement therapies for rare diseases: a breeze for regulatory approval? Gorzelany JA; de Souza MP Sci Transl Med; 2013 Mar; 5(178):178fs10. PubMed ID: 23536010 [TBL] [Abstract][Full Text] [Related]
28. Adopting orphan drugs--two dozen years of treating rare diseases. Haffner ME N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556 [No Abstract] [Full Text] [Related]
36. Promoting the development of drugs against rare diseases: what more should be done? Westermark K; Llinares J Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396 [No Abstract] [Full Text] [Related]
37. [The legal regulation of life cycle of orphan pharmaceuticals]. Gildeyeva GN; Kartavtsova TV Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041 [TBL] [Abstract][Full Text] [Related]
38. [Hope for patients with rare diseases--"orphan" drugs]. Kuzelová M; Kubácková K; Palágyi M; Smíd M Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930 [TBL] [Abstract][Full Text] [Related]